Search documents
公司点评报告:研发驱动成长,执行器项目进展迅速
Guoyuan Securities· 2024-04-29 02:30
[Table_Main] 公司研究|可选消费|汽车与汽车零部件 证券研究报告 拓普集团(601689)公司点评报告 2024年04月27日 业绩如研期兑发现驱,北动美整成体转长盈, 执行器项目进展迅速 [Table_Inves 买t] 入|维持 ——拓普集团(601689)公司点评报告 [事Ta件ble:_S ummary] [当Ta前b价le_/目Ta标rg价etP:r 5ic 9e.7] 9元/76.53元 公司发布 2023 年年报,业绩符合我们预期。2023 年实现营收 197.01 亿 目标期限: 6 个月 元,同比+23.18%;实现归母净利润 21.51 亿元,同比+26.50%;实现扣 [基Ta本bl数e_据Ba se] 非归母净利润20.21亿元,同比+22.07%。2023年Q4实现营收55.49亿 52周最高/最低价(元): 81.2 / 45.21 元,同比+13.49%,环比+11.17%;实现归母净利润 5.54 亿元,同比 A股流通股(百万股): 1102.05 +12.64%,环比+10.05%;实现扣非归母净利润5.20亿元,同比+8.05%, A股总股本(百万股): 116 ...
贵州茅台2024一季报点评:韧性充足,Q1稳健增长
Guoyuan Securities· 2024-04-29 02:30
[Table_Main] 公司研究|日常消费|食品、饮料与烟草 证券研究报告 [Table_Invest]买入|维持 贵州茅台(600519)公司点评报告 2024 年 04 月 28 日 [Table_Title] 韧性充足,Q1 稳健增长 ——贵州茅台 2024 一季报点评 [Table_Summary] 事件 公司公告 2024 一季报。24Q1,公司实现总营收 464.85 亿元,同比+18.04%, 归母净利 240.65 亿元,同比+15.73%,扣非归母净利 240.51 亿元,同比 +15.75%。 Q1 批发渠道提速,茅台酒、系列酒均稳健增长 1)茅台酒、系列酒收入均实现双位数增长。24Q1,公司茅台酒/系列酒分 别实现收入 397.07/59.36 亿元,同比分别+17.75%/+18.39%,茅台酒收入 占主营业务收入的 86.99%,同比-0.06pct。 2)批发渠道收入较快增长,直销渠道表现稳健。24Q1,公司直销/批发渠 道分别实现收入 193.19/263.24 亿元,同比分别+8.49%/+25.78%,直销收 入占主营业务收入的 42.33%,同比-3.64pct。24Q1 ...
2024年一季度报告点评:新签订单保持高增长,看好高增业绩持续
Guoyuan Securities· 2024-04-28 01:30
[Table_TargetPrice] 百诚医药(301096)公司点评报告 2024 年 04 月 27 日 [Table_Summary] 事件: 百诚医药近期发布 2023 年及 2024 年一季度报告:2023 年公司实现收入 10.2 亿(+67.5%),主要系公司抓住国内药物研发 CRO 市场的良好发展机 遇,深化与客户的战略合作关系,加强研发团队的建设,持续提升公司核心 竞争力;新增订单金额为 13.6 亿(含税,+35.1%),充足的订单为公司业 绩增长提供保障;实现归母净利润 2.7 亿(+40.1%)、扣非归母净利润 2.6 亿(+52.5%)。2024Q1 公司实现收入 2.2 亿(+34.0%)、归母净利润 4981.8 万(+42.1%)、扣非归母净利润 4872.2 万(+41.0%)。。 研发技术服务与权益分成协同链条打通,实现项目价值最大化 分业务看:2023 年临床前药学研究收入 3.4 亿(+54.8%)、研发技术成果 转化 3.9 亿(+77.7%)、临床服务 1.9 亿(+141.3%)、CDMO 5249.3 万 (+152.4%)及权益分成 2962.6 万(-48 ...
2023年年报及2024年一季报点评:经营业绩稳健增长,创新业务空间广阔
Guoyuan Securities· 2024-04-28 01:30
[Table_Main] 公司研究|信息技术|技术硬件与设备 证券研究报告 海康威视(002415)公司点评报告 2024年04月26日 [Table_Invest] [Tab经le_T营itle业] 绩稳健增长,创新业务空间广阔 买入|维持 ——海康威视(002415.SZ)2023年年报及 2024 年一季报点评 [当Ta前b价le_:T argetPr3ic2e.6] 4元 [事Ta件ble:_S ummary] 公司于2024年4月19日收盘后发布《2023年年度报告》、《2024年第一 [基Ta本bl数e_据Ba se] 季度报告》。 52周最高/最低价(元): 37.90 / 30.35 点评: A股流通股(百万股): 9108.32 2023年经营绩效逐季改善,创新业务是亮点 A股总股本(百万股): 9330.60 2023年,公司经营绩效逐季改善,全年实现营业收入893.40亿元,同比增 流通市值(百万元): 297295.51 长7.42%;实现归母净利润141.08亿元,同比增长9.89%;实现扣非归母 总市值(百万元): 304550.81 净利润136.66亿元,同比增长10.83 ...
嘉必优2023年报及2024年一季报点评:Q1收入+33%,经营逐步改善
Guoyuan Securities· 2024-04-28 01:30
Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Insights - The company reported a total revenue of 444 million yuan in 2023, a year-on-year increase of 2.39%, and a net profit attributable to shareholders of 91 million yuan, up 41.95% [4]. - The first quarter of 2024 saw a significant revenue increase of 33.34% year-on-year, reaching 117 million yuan, with a net profit of 24 million yuan, up 69.93% [4]. - The implementation of new national standards is expected to boost domestic demand, while overseas revenue is projected to recover in the second half of 2023 [4]. Financial Data and Valuation - Revenue (in million yuan): - 2022: 433.42 - 2023: 443.80 - 2024E: 563.49 - 2025E: 700.88 - 2026E: 856.31 - Year-on-year revenue growth rates: - 2022: 23.44% - 2023: 2.39% - 2024E: 26.97% - 2025E: 24.38% - 2026E: 22.18% [2]. - Net profit attributable to shareholders (in million yuan): - 2022: 64.37 - 2023: 91.37 - 2024E: 119.03 - 2025E: 153.37 - 2026E: 191.52 - Year-on-year net profit growth rates: - 2022: -49.94% - 2023: 41.95% - 2024E: 30.27% - 2025E: 28.85% - 2026E: 24.88% [2]. - The company’s P/E ratios for 2024, 2025, and 2026 are projected to be 20.72, 16.08, and 12.87 respectively [4]. Business Performance - The company’s human nutrition business showed steady growth, while personal care and cosmetics experienced rapid growth [4]. - The implementation of new standards for infant formula is expected to increase the demand for ARA and DHA [4]. - The company’s gross margin for 2023 was 42.40%, with a net profit margin of 20.59%, reflecting improvements in management expenses and reduced impairment losses [4].
汤臣倍健2024年一季报点评:高基数短期扰动,费用投入同比加大
Guoyuan Securities· 2024-04-28 01:30
[Table_Main] 公司研究|日常消费|食品、饮料与烟草 证券研究报告 汤臣倍健(300146)公司点评报告 2024年04月26日 [Table高_Tit基le] 数短期扰动,费用投入同比加大 [Table_Inves 买t] 入|维持 ——汤臣倍健 2024 年一季报点评 [报Ta告ble要_S点um:m ary] [ Table_TargetPr ice] 事件 公司公告2024年一季报。2024Q1,公司实现总收入26.46亿元(-14.87%), [基Ta本bl数e_据Ba se] 归母净利7.27亿元(-29.43%),扣非归母净利7.09亿元(-28.67%)。 52周最高/最低价(元): 24.34 / 14.84 高基数下收入有所下滑,销售费用投入增加 1)高基数下,一季度收入有所下滑。2024Q1,公司收入同比-14.87%至 A股流通股(百万股): 1129.99 26.46亿元(2023Q1收入同比+36.30%)。 A股总股本(百万股): 1700.85 2)销售费用投入有所增加。2024Q1,公司毛利率为69.90%,同比-0.42pct, 流通市值(百万元): 17 ...
山西汾酒2023年报及2024一季报点评:23年圆满收官,持续高质量发展
Guoyuan Securities· 2024-04-28 01:30
[Table_Main] 公司研究|日常消费|食品、饮料与烟草 证券研究报告 山西汾酒(600809)公司点评报告 2024年4月26日 [Table_Ti2tle3] 年圆满收官,持续高质量发展 [Table_Inves 买t] 入|维持 ——山西汾酒 2023 年报及 2024 一季报点评 [T abl事e_件Su mmary] [基Ta本bl数e_据Ba se] 公司公告 2023 年报及 2024 一季报。23 年,公司实现总营收 319.28 亿元 52周最高/最低价(元): 262.82 / 185.07 (+21.80%),归母净利104.38亿元(+28.93%)。23Q4,公司实现总营收51.84 A股流通股(百万股): 1219.96 亿元(+27.38%),归母净利 10.07 亿元(+1.95%)。24Q1,公司实现总营收 153.38亿元(+20.94%),归母净利62.62亿元(+29.95%)。公司拟每股派发 A股总股本(百万股): 1219.96 现金股利4.37元(含税),分红率51.07%。 流通市值(百万元): 307784.77 产品结构持续升级,全国化进程持续推 ...
五芳斋2023年报及2024年一季报点评:高分红回报股东,盈利水平稳健
Guoyuan Securities· 2024-04-28 01:30
Investment Rating - The report maintains a rating of "Accumulate" for the company [1][6]. Core Views - The company has shown stable profitability and is actively expanding its distribution channels [6]. - The revenue for 2023 reached 2.635 billion yuan, representing a year-on-year growth of 7.04%, while the net profit attributable to shareholders was 165.74 million yuan, up 19.74% year-on-year [6]. - The company plans to distribute a cash dividend of 1 yuan per share (including tax) and a stock bonus of 0.4 shares, resulting in a total dividend payout ratio of 114.70% when including share buybacks [6]. Financial Data and Valuation - **Revenue (Million Yuan)**: - 2022A: 2462.10 - 2023A: 2635.31 - 2024E: 2920.88 - 2025E: 3209.65 - 2026E: 3496.48 - **Year-on-Year Revenue Growth (%)**: - 2022A: -14.87 - 2023A: 7.04 - 2024E: 10.84 - 2025E: 9.89 - 2026E: 8.94 - **Net Profit (Million Yuan)**: - 2022A: 138.41 - 2023A: 165.74 - 2024E: 197.58 - 2025E: 228.85 - 2026E: 256.52 - **Year-on-Year Net Profit Growth (%)**: - 2022A: -28.53 - 2023A: 19.74 - 2024E: 19.21 - 2025E: 15.83 - 2026E: 12.09 - **Return on Equity (ROE, %)**: - 2022A: 8.25 - 2023A: 9.40 - 2024E: 10.67 - 2025E: 11.90 - 2026E: 12.85 - **Earnings Per Share (EPS, Yuan)**: - 2022A: 0.96 - 2023A: 1.15 - 2024E: 1.37 - 2025E: 1.59 - 2026E: 1.78 - **Price-to-Earnings Ratio (P/E)**: - 2024E: 28.37 - 2025E: 23.69 - 2026E: 19.87 - 2027E: 17.16 - 2028E: 15.31 [2][6].
公司23年年报及24Q1季报点评:汽车电子业务持续高增,XR弹性24年逐步兑现
Guoyuan Securities· 2024-04-28 01:30
兆威机电(003021)公司点评报告 2024 年 04 月 25 日 ——公司 23 年年报及 24Q1 季报点评 在人工智能带动的终端装置智能化应用升级的过程中,微型传动系统 的重要性在不断提升。我们重点看好 XR 放量和汽车电子新项目开发对于公 司业绩的显著带动。预测公司 24 年归母净利润 2.4 亿元,给予 60xPE,对 应股价 85.3 元,维持"买入"的投资评级。 | --- | --- | --- | --- | --- | |---------------------------------------------------|-------|---------------------------------|-------|-------| | 附表:盈利预测 [Table_Finance] 财务数据和估值 | 2023 | 2024E | 2025E | 2026E | | 营业收入(百万元) | | 1205.95 1672.53 2232.03 2539.94 | | | | 增长率( % ) | | 4.64 38.69 33.45 13.79 | | | | 归母净利润 | | ...
新乳业2023年报及2024年一季报点评:鲜奶业务跑赢行业,盈利能力稳步提升
Guoyuan Securities· 2024-04-28 01:30
Investment Rating - The report maintains a "Buy" rating for the company [3]. Core Views - The company focuses on low-temperature fresh milk, with a 54% year-on-year increase in net profit excluding non-recurring items in Q3 [9]. - The company's revenue for 2023 is projected to be 10.99 billion yuan, with a year-on-year growth of 9.80% [9]. - The company is expected to achieve net profits of 5.61 billion yuan, 7.09 billion yuan, and 8.56 billion yuan for 2024, 2025, and 2026 respectively, with growth rates of 30.24%, 26.36%, and 20.78% [9]. Financial Summary - Revenue for 2023 is 10,987.29 million yuan, with a year-on-year increase of 9.80% [5]. - Net profit attributable to shareholders for 2023 is 430.83 million yuan, reflecting a 19.27% increase year-on-year [5]. - The company's gross profit margin for 2023 is 26.87%, up 2.84 percentage points year-on-year [9]. - The company’s return on equity (ROE) for 2023 is 16.85% [5]. Business Performance - The liquid milk and milk powder segments showed steady growth, with revenues of 9,755 million yuan and 790 million yuan respectively, both increasing by over 11% year-on-year [9]. - The company’s distribution channels have expanded, with a 42.74% year-on-year increase in distributor revenue in the second half of 2023 [9]. - The company has launched new products, with new product revenue accounting for 12% of total revenue in 2023 [9]. Market Position - The company has maintained a strong market share in the fresh milk segment, with a nearly 40% year-on-year growth in its high-end product line [9]. - The company’s online direct sales revenue increased by 20.51% year-on-year, indicating robust growth in e-commerce channels [9]. Future Outlook - The company is expected to continue its growth trajectory, with projected revenues of 12.22 billion yuan, 13.48 billion yuan, and 14.73 billion yuan for 2024, 2025, and 2026 respectively [5]. - The price-to-earnings (P/E) ratio is projected to decrease from 15 in 2024 to 10 in 2026, indicating potential for value appreciation [9].